ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $2,013,633 | – | 50,798 | – | 0.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital LLC | 7,083,288 | $135,007,469 | 37.72% |
| Lynx1 Capital Management LP | 3,813,926 | $72,693,429 | 28.58% |
| GREAT POINT PARTNERS LLC | 3,703,433 | $70,587,433 | 12.03% |
| Ally Bridge Group (NY) LLC | 357,271 | $6,809,585 | 4.06% |
| Octagon Capital Advisors LP | 1,241,300 | $23,659,178 | 3.79% |
| Exome Asset Management LLC | 173,500 | $3,306,910 | 3.27% |
| Frazier Life Sciences Management, L.P. | 3,131,008 | $59,677,012 | 3.19% |
| Nan Fung Group Holdings Ltd | 263,940 | $5,030,696 | 3.13% |
| Paradigm Biocapital Advisors LP | 3,176,743 | $60,548,722 | 2.84% |
| COMMODORE CAPITAL LP | 1,610,000 | $30,686,600 | 2.68% |